Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Stephen V. Liu is an Assistant Professor of Medicine and a practicing thoracic medical oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University. He received his undergraduate degree at Johns Hopkins University and his medical degree at the University of Maryland. He then completed his internship and residency in Internal Medicine at the University of Pennsylvania and his fellowship training in Hematology and Oncology at the University of Southern California before joining the faculty of Georgetown University. Dr.

Join Us! 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know
Anonymous
Author
Stephen Liu, MD, GRACE Faculty

 
 
The Global Resource for Advancing Cancer Education (GRACE)
in partnership with Georgetown University Hospital
is pleased to present
 

2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know

Saturday, Nov. 18, 2017 | 1 - 3:30 pm; Leavey Center at Georgetown Hospital 
 
 
 
Suggested donation $15

 

 

 

How does immunotherapy work? Presented by Alex Spira, M.D., Ph.D., F.A.C.P. Virginia Cancer Specialists


 

 

Who should get immunotherapy for lung cancer? Presented by Benjamin Levy, MD Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital


 

 

What are the side effects? Presented by Stephen Liu, MD Lombardi Cancer Center, Georgetown University Hospital


 

 

 

Navigating clinical trials? Panel discussion


 

Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

 

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on